|
US101A
(en)
|
|
1836-12-06 |
|
Method of jcakibtg and furling iw sails fob ships |
|
US10584A
(en)
|
|
1854-02-28 |
|
Bank-lock |
|
DE69740140D1
(de)
|
1996-07-24 |
2011-04-14 |
Celgene Corp |
Substituierte 2-(2,6-Dioxopiperidin-3-yl)-phthalimide und Oxoisoindoline und Verfahren zur Verringerung der TNF-Alpha-Stufen
|
|
ATE460423T1
(de)
|
1997-05-14 |
2010-03-15 |
Sloan Kettering Inst Cancer |
Verfahren und zubereitungen zur zerstörung bestimmter proteine
|
|
SK9192000A3
(en)
|
1997-12-17 |
2001-03-12 |
Merck & Co Inc |
Integrin receptor antagonists
|
|
US6306663B1
(en)
|
1999-02-12 |
2001-10-23 |
Proteinex, Inc. |
Controlling protein levels in eucaryotic organisms
|
|
EP1176959B1
(en)
|
1999-05-05 |
2006-03-08 |
Merck & Co., Inc. |
Novel prolines as antimicrobial agents
|
|
HUP0303172A3
(en)
|
2000-06-28 |
2006-05-29 |
Bristol Myers Squibb Co |
Selective androgen receptor modulators and methods for their identification, desing and use
|
|
AU2001295041A1
(en)
|
2000-09-08 |
2002-03-22 |
California Institute Of Technology |
Proteolysis targeting chimeric pharmaceutical
|
|
US7208157B2
(en)
|
2000-09-08 |
2007-04-24 |
California Institute Of Technology |
Proteolysis targeting chimeric pharmaceutical
|
|
RU2298554C2
(ru)
|
2000-09-19 |
2007-05-10 |
Бристол-Маерс Сквибб Компани |
Конденсированные гетероциклические сукцинимидные соединения
|
|
US20030045552A1
(en)
|
2000-12-27 |
2003-03-06 |
Robarge Michael J. |
Isoindole-imide compounds, compositions, and uses thereof
|
|
US7091353B2
(en)
|
2000-12-27 |
2006-08-15 |
Celgene Corporation |
Isoindole-imide compounds, compositions, and uses thereof
|
|
WO2002066512A1
(en)
|
2001-02-16 |
2002-08-29 |
E.I. Dupont De Nemours And Company |
Angiogenesis-inhibitory tripeptides, compositions and their methods of use
|
|
HN2002000136A
(es)
|
2001-06-11 |
2003-07-31 |
Basf Ag |
Inhibidores de la proteasa del virus hiv, compuestos que contienen a los mismos, sus usos farmaceuticos y los materiales para su sintesis
|
|
ATE508725T1
(de)
|
2001-06-20 |
2011-05-15 |
Takeda Pharmaceutical |
Verfahren zur herstellung von tabletten
|
|
DE60231989D1
(de)
|
2001-08-06 |
2009-05-28 |
Childrens Medical Center |
Antiangiogenese wirkung von stickstoffsubstituierten thalidomid-analoga
|
|
US7030141B2
(en)
|
2001-11-29 |
2006-04-18 |
Christopher Franklin Bigge |
Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
|
|
US20060004029A1
(en)
|
2002-08-30 |
2006-01-05 |
Akihiko Tsuruoka |
Nitrogen-containing aromatic derivatives
|
|
MXPA06015169A
(es)
|
2004-07-08 |
2007-08-21 |
Warner Lambert Co |
Moduladores de androgenos.
|
|
CN100383139C
(zh)
|
2005-04-07 |
2008-04-23 |
天津和美生物技术有限公司 |
可抑制细胞释放肿瘤坏死因子的哌啶-2,6-二酮衍生物
|
|
US20060252698A1
(en)
|
2005-04-20 |
2006-11-09 |
Malcolm Bruce A |
Compounds for inhibiting cathepsin activity
|
|
CA2822094C
(en)
|
2005-08-31 |
2015-10-27 |
Celgene Corporation |
Isoindole-imide compounds and compositions comprising and methods of using the same
|
|
WO2007106670A2
(en)
|
2006-03-03 |
2007-09-20 |
Novartis Ag |
N-formyl hydroxylamine compounds
|
|
NZ596260A
(en)
|
2006-03-29 |
2013-05-31 |
Univ California |
Diarylthiohydantoin compounds
|
|
AU2007275415A1
(en)
|
2006-07-20 |
2008-01-24 |
Ligand Pharmaceuticals Incorporated |
Proline urea CCR1 antagonists for the treatment of autoimmune diseases or inflammation
|
|
AU2007290407A1
(en)
|
2006-08-30 |
2008-03-06 |
Celgene Corporation |
5-substituted isoindoline compounds
|
|
RU2448101C2
(ru)
|
2006-08-30 |
2012-04-20 |
Селджин Корпорейшн |
5-замещенные изоиндолиновые соединения
|
|
US8877780B2
(en)
|
2006-08-30 |
2014-11-04 |
Celgene Corporation |
5-substituted isoindoline compounds
|
|
WO2008054827A2
(en)
|
2006-11-03 |
2008-05-08 |
Pharmacyclics, Inc. |
Bruton's tyrosine kinase activity probe and method of using
|
|
US8415340B2
(en)
|
2007-07-25 |
2013-04-09 |
Bristol-Myers Squibb Company |
Triazine kinase inhibitors
|
|
CA2694953C
(en)
|
2007-07-31 |
2015-12-01 |
Androscience Corporation |
Compositions including androgen receptor degradation (ard) enhancers and methods of prophylactic or therapeutic treatment of skin disorders and hair loss
|
|
CA2957226C
(en)
|
2008-10-29 |
2018-08-14 |
Celgene Corporation |
Isoindoline compounds for use in the treatment of cancer
|
|
AU2010223105B2
(en)
|
2009-03-09 |
2016-05-12 |
Spi Pharma, Inc. |
Highly compactable and durable direct compression excipients and excipient systems
|
|
WO2010141805A1
(en)
|
2009-06-05 |
2010-12-09 |
Janssen Pharmaceutica Nv |
Heterocyclic amides as modulators of trpa1
|
|
WO2011008260A2
(en)
|
2009-07-13 |
2011-01-20 |
President And Fellows Of Harvard College |
Bifunctional stapled polypeptides and uses thereof
|
|
AR078793A1
(es)
|
2009-10-27 |
2011-12-07 |
Orion Corp |
Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros
|
|
SG183257A1
(en)
|
2010-02-11 |
2012-09-27 |
Celgene Corp |
Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
|
|
EP2588129A4
(en)
|
2010-06-30 |
2014-07-09 |
Univ Brandeis |
ON SMALL MOLECULES TARGETED PROTEIN REMOVAL
|
|
JP5852658B2
(ja)
|
2010-09-24 |
2016-02-03 |
ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン |
デユビキチナーゼ阻害剤およびその使用方法
|
|
EP2649099A4
(en)
|
2010-12-07 |
2016-10-19 |
Univ Yale |
SMALL MOLECULAR HYDROPHOBIC LABELING OF FUSION PROTEINS AND INDUCED REMOVAL FROM THIS
|
|
WO2012090104A1
(en)
|
2010-12-31 |
2012-07-05 |
Kareus Therapeutics, Sa |
Methods and compositions for designing novel conjugate therapeutics
|
|
JP5964407B2
(ja)
|
2011-04-21 |
2016-08-03 |
オリオン コーポレーション |
アンドロゲン受容体調節カルボキシアミド
|
|
WO2012149299A2
(en)
|
2011-04-29 |
2012-11-01 |
Celgene Corporaiton |
Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
|
|
KR102438072B1
(ko)
|
2012-01-12 |
2022-08-31 |
예일 유니버시티 |
E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
|
|
WO2013106646A2
(en)
|
2012-01-12 |
2013-07-18 |
Yale University |
Compounds and methods for the inhibition of vcb e3 ubiquitin ligase
|
|
US20140079636A1
(en)
|
2012-04-16 |
2014-03-20 |
Dinesh U. Chimmanamada |
Targeted therapeutics
|
|
WO2013170147A1
(en)
|
2012-05-11 |
2013-11-14 |
Yale University |
Compounds useful for promoting protein degradation and methods using same
|
|
MA37711A1
(fr)
*
|
2012-06-04 |
2017-05-31 |
Pharmacyclics Inc |
Formes cristallines d'un inhibiteur de tyrosine kinase de bruton
|
|
WO2014015157A2
(en)
|
2012-07-19 |
2014-01-23 |
Philadelphia Health & Education Corporation |
Novel sigma receptor ligands and methods of modulating cellular protein homeostasis using same
|
|
GB201311910D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel Compounds
|
|
NL2011274C2
(en)
|
2013-08-06 |
2015-02-09 |
Illumicare Ip B V 51 |
Groundbreaking platform technology for specific binding to necrotic cells.
|
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
|
EP3738594A1
(en)
|
2013-09-10 |
2020-11-18 |
Madrigal Pharmaceuticals, Inc. |
Targeted therapeutics having an hsp90 ligand as binding moiety
|
|
WO2015114314A1
(en)
|
2014-01-28 |
2015-08-06 |
Cipla Limited |
Pharmaceutical composition comprising abiraterone
|
|
JP6576942B6
(ja)
|
2014-03-03 |
2019-11-27 |
マドリガル ファーマシューティカルズ インコーポレイテッド |
標的治療薬
|
|
EP4649963A3
(en)
|
2014-04-14 |
2026-05-13 |
Arvinas Operations, Inc. |
Imide-based modulators of proteolysis and associated methods of use
|
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
US20160058872A1
(en)
|
2014-04-14 |
2016-03-03 |
Arvinas, Inc. |
Imide-based modulators of proteolysis and associated methods of use
|
|
TW201613916A
(en)
|
2014-06-03 |
2016-04-16 |
Gilead Sciences Inc |
TANK-binding kinase inhibitor compounds
|
|
US20160022642A1
(en)
|
2014-07-25 |
2016-01-28 |
Yale University |
Compounds Useful for Promoting Protein Degradation and Methods Using Same
|
|
US10071164B2
(en)
|
2014-08-11 |
2018-09-11 |
Yale University |
Estrogen-related receptor alpha based protac compounds and associated methods of use
|
|
RS59490B1
(sr)
|
2014-11-21 |
2019-12-31 |
Biohaven Therapeutics Ltd |
Sublingvalna formulacija riluzola
|
|
WO2016097071A1
(en)
|
2014-12-18 |
2016-06-23 |
F. Hoffmann-La Roche Ag |
Estrogen receptor modulators and uses thereof
|
|
US9694084B2
(en)
|
2014-12-23 |
2017-07-04 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
JP6815318B2
(ja)
|
2014-12-23 |
2021-01-20 |
ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド |
二官能性分子によって標的化タンパク質分解を誘導する方法
|
|
US12312316B2
(en)
|
2015-01-20 |
2025-05-27 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
JP6817962B2
(ja)
|
2015-01-20 |
2021-01-20 |
アルビナス・オペレーションズ・インコーポレイテッドArvinas Operations, Inc. |
ターゲティングされたアンドロゲン受容体分解のための化合物および方法
|
|
GB201504314D0
(en)
|
2015-03-13 |
2015-04-29 |
Univ Dundee |
Small molecules
|
|
AU2016232705C1
(en)
|
2015-03-18 |
2021-06-17 |
Arvinas, Inc. |
Compounds and methods for the enhanced degradation of targeted proteins
|
|
GB201506872D0
(en)
|
2015-04-22 |
2015-06-03 |
Ge Oil & Gas Uk Ltd |
Novel compounds
|
|
GB201506871D0
(en)
|
2015-04-22 |
2015-06-03 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
CA2988414C
(en)
|
2015-06-04 |
2023-09-26 |
Arvinas, Inc. |
Imide-based modulators of proteolysis and associated methods of use
|
|
WO2016197114A1
(en)
|
2015-06-05 |
2016-12-08 |
Arvinas, Inc. |
Tank-binding kinase-1 protacs and associated methods of use
|
|
WO2017007612A1
(en)
|
2015-07-07 |
2017-01-12 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
EP3319944A4
(en)
|
2015-07-10 |
2019-04-24 |
Arvinas, Inc. |
MDM2-BASED MODULATORS OF PROTEOLYSIS AND RELATED USE METHODS
|
|
CA2988436A1
(en)
|
2015-07-13 |
2017-01-19 |
Arvinas, Inc. |
Alanine-based modulators of proteolysis and associated methods of use
|
|
EP3337476A4
(en)
|
2015-08-19 |
2019-09-04 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of bromodomain-containing proteins
|
|
BR112018008918A8
(pt)
|
2015-11-02 |
2019-02-26 |
Univ Yale |
compostos de quimera proteólise dirigida e métodos para preparação e uso dos mesmos
|
|
KR101859074B1
(ko)
|
2016-01-28 |
2018-05-18 |
이화여자대학교 산학협력단 |
신규한 글라이신 아미드 화합물 또는 이의 약학적으로 허용 가능한 염, 이의 제조방법 및 이를 포함하는 소듐 채널 활성 관련 질환의 예방 또는 치료용 약학적 조성물
|
|
US20170281784A1
(en)
|
2016-04-05 |
2017-10-05 |
Arvinas, Inc. |
Protein-protein interaction inducing technology
|
|
CN109152933B
(zh)
|
2016-04-21 |
2022-12-02 |
生物风险投资有限责任公司 |
诱导抗细胞凋亡bcl-2家族蛋白的降解的化合物及其用途
|
|
WO2017185031A1
(en)
|
2016-04-22 |
2017-10-26 |
Dana-Farber Cancer Institute, Inc. |
Degradation of cyclin-dependent kinase 4/6 (cdk4/6) by conjugation of cdk4/6 inhibitors with e3 ligase ligand and methods of use
|
|
US10865205B2
(en)
|
2016-04-22 |
2020-12-15 |
Dana-Farber Cancer Institute, Inc. |
Degradation of cyclin-dependent kinase 8 (CDK8) by conjugation of CDK8 inhibitors with E3 ligase ligand and methods of use
|
|
WO2017197046A1
(en)
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
C3-carbon linked glutarimide degronimers for target protein degradation
|
|
CN121974842A
(zh)
|
2016-05-10 |
2026-05-05 |
C4医药公司 |
用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
|
|
WO2017197056A1
(en)
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
Bromodomain targeting degronimers for target protein degradation
|
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
|
EP3512842B1
(en)
|
2016-09-15 |
2024-01-17 |
Arvinas, Inc. |
Indole derivatives as estrogen receptor degraders
|
|
SI3526202T1
(sl)
|
2016-10-11 |
2025-04-30 |
Arvinas Operations, Inc. |
Spojine in postopki za ciljno razgradnjo androgenskih receptorjev
|
|
AU2017363257B2
(en)
|
2016-11-22 |
2021-08-19 |
Dana-Farber Cancer Institute, Inc. |
Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use
|
|
FR3064633B1
(fr)
|
2017-03-28 |
2019-04-12 |
Ecole Polytechnique |
Nouveaux composes de type dithiospirocetals et leur utilisation
|
|
CA3062161A1
(en)
|
2017-05-01 |
2018-11-08 |
Spg Therapeutics, Inc. |
Tripartite androgen receptor eliminators, methods and uses thereof
|
|
KR102119465B1
(ko)
|
2017-09-20 |
2020-06-08 |
(주)아모레퍼시픽 |
트리메톡시 페닐 화합물 및 그를 포함하는 발모 또는 육모 촉진용 조성물
|
|
CN110746399B
(zh)
|
2018-07-23 |
2022-04-22 |
上海美志医药科技有限公司 |
具有降解雄激素受体活性的化合物
|
|
WO2020047487A1
(en)
|
2018-08-31 |
2020-03-05 |
The Regents Of The University Of California |
Methods for treating cancer with rorgamma inhibitors and statins
|
|
AU2019404022A1
(en)
|
2018-12-19 |
2021-07-08 |
Celgene Corporation |
Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith
|
|
BR112021011968A2
(pt)
|
2018-12-19 |
2021-09-08 |
Celgene Corporation |
Compostos de 3-((3-aminofenil)amino)piperidina-2,6-diona substituídos, composições dos mesmos e métodos de tratamento com os mesmos
|
|
EP3897631A4
(en)
|
2018-12-20 |
2022-11-23 |
C4 Therapeutics, Inc. |
TARGETED PROTEIN BREAKDOWN
|
|
US11547759B2
(en)
|
2019-01-30 |
2023-01-10 |
Montelino Therapeutics, Inc. |
Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
|
|
WO2020160295A1
(en)
|
2019-01-30 |
2020-08-06 |
Montelino Therapeutics, Llc |
Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
|
|
JP2022521825A
(ja)
|
2019-03-28 |
2022-04-12 |
エッサ ファーマ,インコーポレイテッド |
アンドロゲン受容体モジュレーター及びタンパク質分解誘導キメラリガンドとして使用するための方法
|
|
US12109179B2
(en)
|
2019-03-28 |
2024-10-08 |
Essa Pharma Inc. |
Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof
|
|
US12331061B2
(en)
|
2019-04-18 |
2025-06-17 |
Accutar Biotechnology Inc. |
Compounds having BET, estrogen receptor, and androgen receptor degradation activity and uses thereof
|
|
BR112021020775A2
(pt)
*
|
2019-04-18 |
2021-12-14 |
Hinova Pharmaceuticals Inc |
Classe de compostos heterocíclicos quiméricos bifuncionais para a degradação direcionada de receptores de andrógeno e uso dos mesmos
|
|
JP2022533147A
(ja)
|
2019-05-17 |
2022-07-21 |
ヒノバ ファーマシューティカルズ インコーポレイテッド |
芳香族アミン類のar及びbetを標的とするタンパク質分解キメラ化合物及び使用
|
|
AU2020348849A1
(en)
|
2019-09-19 |
2022-04-07 |
The Regents Of The University Of Michigan |
Spirocyclic androgen receptor protein degraders
|
|
EP4034114A4
(en)
|
2019-09-23 |
2023-07-26 |
Accutar Biotechnology Inc. |
Novel ureas having androgen receptor degradation activity and uses thereof
|
|
EP3795570B1
(en)
|
2019-09-23 |
2022-02-23 |
Accutar Biotechnology Inc. |
Substituted quinoline-8-carbonitrile derivatives having androgen receptor degradation activity and uses thereof
|
|
WO2021061644A1
(en)
|
2019-09-23 |
2021-04-01 |
Accutar Biotechnology Inc. |
Novel substituted quinoline-8-carbonitrile derivatives with androgen receptor degradation activity and uses thereof
|
|
US20210113557A1
(en)
|
2019-10-22 |
2021-04-22 |
Arvinas Operations, Inc. |
Methods of treating prostate cancer
|
|
AU2020414151A1
(en)
|
2019-12-23 |
2022-08-25 |
Jiangxi Jemincare Group Co., Ltd |
Protein degradation agent compound preparation method and application
|
|
CN113582974B
(zh)
|
2020-04-30 |
2022-05-17 |
江西济民可信集团有限公司 |
一类作为蛋白降解剂的化合物及其制备方法和医药用途
|
|
KR20230015934A
(ko)
|
2020-05-12 |
2023-01-31 |
아비나스 오퍼레이션스, 인코포레이티드 |
전립선암 치료 방법
|
|
KR20230024328A
(ko)
|
2020-06-12 |
2023-02-20 |
상하이 제민케어 파마슈티칼스 컴퍼니 리미티드 |
프탈라지논 화합물, 이의 제조 방법 및 이의 의학적 용도
|
|
IL299256A
(en)
|
2020-06-24 |
2023-02-01 |
Celgene Corp |
Cerebellum binding compounds, their compounds and methods of treatment with them
|
|
ES3047718T3
(en)
|
2020-06-24 |
2025-12-04 |
Celgene Corp |
Cereblon binding compounds, compositions thereof, and methods of treatment therewith
|
|
JP7778095B2
(ja)
|
2020-06-24 |
2025-12-01 |
セルジーン コーポレーション |
セレブロン結合化合物、その組成物及びそれによる治療方法
|
|
CN117327059A
(zh)
|
2020-07-08 |
2024-01-02 |
北京泰德制药股份有限公司 |
抑制并诱导蛋白降解的化合物
|
|
WO2022048605A1
(zh)
|
2020-09-04 |
2022-03-10 |
南昌奥瑞药业有限公司 |
一种杂环化合物、其制备方法、中间体、组合物以及应用
|
|
CN114163444B
(zh)
|
2020-09-11 |
2023-07-14 |
江苏恒瑞医药股份有限公司 |
一种用于雄激素受体蛋白靶向降解的嵌合体化合物、其制备方法及其在医药上的应用
|
|
WO2022087125A1
(en)
|
2020-10-21 |
2022-04-28 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor protein
|
|
EP4240733A1
(en)
|
2020-11-06 |
2023-09-13 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor and associated methods of use
|
|
CN116529248B
(zh)
|
2020-11-25 |
2025-10-17 |
西藏海思科制药有限公司 |
一种苯环衍生物及其组合物和药学上的应用
|
|
US20220184078A1
(en)
|
2020-12-11 |
2022-06-16 |
Arvinas Operations, Inc. |
Methods of treating prostate cancer
|
|
US12152035B2
(en)
|
2020-12-30 |
2024-11-26 |
Industrial Technology Research Institute |
Androgen receptor binding molecule and use thereof
|
|
CN114853846A
(zh)
|
2021-02-04 |
2022-08-05 |
苏州国匡医药科技有限公司 |
一种雄激素受体降解剂及其应用
|
|
WO2022187419A1
(en)
|
2021-03-03 |
2022-09-09 |
The Regents Of The University Of Michigan |
Small molecule degraders of androgen receptor
|
|
US12016847B2
(en)
|
2021-03-12 |
2024-06-25 |
Bristol-Myers Squibb Company |
Methods of treating prostate cancer
|
|
CN116891457A
(zh)
|
2022-04-11 |
2023-10-17 |
江苏恒瑞医药股份有限公司 |
一种用于雄激素受体蛋白靶向降解的嵌合体化合物、其制备方法及其在医药上的应用
|
|
WO2023205481A1
(en)
|
2022-04-21 |
2023-10-26 |
Arvinas Operations, Inc. |
A combination for use in treating prostate cancer comprising arv-100 and abiraterone
|
|
CN117065022A
(zh)
|
2022-05-17 |
2023-11-17 |
海创药业股份有限公司 |
一种治疗三阴乳腺癌的药物
|
|
CN117024390B
(zh)
|
2023-08-09 |
2025-11-11 |
中国海洋大学 |
一种Cdc20小分子配体化合物及其降解剂的应用
|